The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.
 
Bailey Gleason Fitzgerald
No Relationships to Disclose
 
Thomas Urban Marron
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Nicole Hall
No Relationships to Disclose
 
Daniel O'Grady
Stock and Other Ownership Interests - Pfizer
 
Nelson LaMarche
No Relationships to Disclose
 
Clotilde Hennequin
Research Funding - Boehringer Ingelheim (Inst); Regeneron (Inst)
 
Samarth Hegde
No Relationships to Disclose
 
Barbara Maier
No Relationships to Disclose
 
Jessica Le Berichel
No Relationships to Disclose
 
Udit Chadda
No Relationships to Disclose
 
Mary Beth Beasley
Consulting or Advisory Role - Abbvie; AstraZeneca/Daiichi Sankyo
Speakers' Bureau - PER
 
David F Yankelevitz
Stock and Other Ownership Interests - Accumetra; American Academic Health System
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Pfizer
Research Funding - Genentech
Patents, Royalties, Other Intellectual Property - General Electric
 
Jorge E. Gomez
Honoraria - BMS
Research Funding - daiichi; JNJ (Inst)
 
Deborah Blythe Doroshow
Consulting or Advisory Role - Atheneum; Boston Healthcare Associates; Dedham Group; Guidepoint Global; Mirati Therapeutics; MJH Life Sciences
Other Relationship - Bristol Myers Squibb Foundation; Conquer Cancer Foundation
 
Rajwanth Veluswamy
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck; Novocure
Speakers' Bureau - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst); Onconova Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Nicholas Cole Rohs
Honoraria - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Genentech; Guardant Health; Jazz Pharmaceuticals; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; MJH Healthcare Holdings, LLC
 
Christian Diego Rolfo
Consulting or Advisory Role - Archer; Boston Pharmaceuticals; Bristol-Myers Squibb; Eisai; Inivata; Merck Serono; Mirati Therapeutics; Novartis
Speakers' Bureau - AstraZeneca; Guardant Health; MSD; Roche Molecular Diagnostics
Research Funding - Lung Cancer Research Foundation
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Fred R. Hirsch
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Merck; Nectin Therapeutics; Novartis; Oncocyte; Sanofi/Regeneron
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
Expert Testimony - Gerson Lehrman Group
 
Miriam Merad
Stock and Other Ownership Interests - Asher Biotherapeutics; Compugen; DAAN Biotherapeutics; Genenta Science; Morphic Therapeutic; Myeloid Therapeutics; Nirogy Therapeutics
Consulting or Advisory Role - Asher Biotherapeutics; Compugen; DAAN Biotherapeutics; Genenta Science; Innate Pharma; Morphic Therapeutic; Myeloid Therapeutics; Nirogy Therapeutics
Research Funding - Boehringer Ingelheim; Genentech; Regeneron; Takeda